Today: 8 June 2026
Browse Category

SWX:ROG.SW 18 November 2025 - 20 December 2025

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

MSCI Europe vs World Indices: Performance, Forecasts and Key Drivers (5–7 December 2025)

The MSCI Europe Index closed at 2,564.76 on Dec. 5, down 0.25% after a recent rally, but remains up about 12.5% to 15.5% year-to-date in 2025. The index outpaces the MSCI World, which is up roughly 7.7% for the year. European stocks continue to trade at lower valuations, with a 3.03% dividend yield and forward P/E of 14.64. The MSCI Europe Index has 402 constituents and a market cap near $12.85 trillion.
7 December 2025
···········
Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

Swiss Stock Market Today, 26 November 2025: SMI Edges Higher as Sentiment Surges and Insurers Face Tougher Rules

The Swiss Market Index closed up 0.07% at 12,781.09 on Wednesday, its highest in about a week, extending a three-day advance. Turnover topped 2.4 million contracts. Investor sentiment jumped after a thaw in Swiss-US trade tensions. Zurich Insurance, Swiss Re, and Swiss Life drew attention after being added to the G20 Financial Stability Board’s insurer resolution list.
26 November 2025
········
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····
Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

Swiss Stock Market Today, November 18, 2025: SMI Slips as Roche Soars, ABB, Zurich and ams-Osram Drag the Index

The Swiss Market Index fell 0.7% to 12,505 by late morning on November 18, 2025, as global equity declines hit financials and industrials. Roche jumped over 6% to a multi-month high after announcing positive phase III results for its breast cancer drug. ABB, Zurich Insurance, and ams-Osram dropped following investor updates and earnings news. Broader European indices also traded sharply lower.
18 November 2025
····

Stock Market Today

  • Ambev Market Outlook: Investor Sentiment Cools
    June 8, 2026, 3:15 AM EDT. The market sentiment for Ambev (ABEV) has recently cooled, reflecting a sober investor stance amid broader economic uncertainties. An experienced analyst with nearly two decades in logistics and a decade in stock investing highlights his diversified holdings across ASEAN and US markets, including Ambev shares. He emphasizes long-term investment balanced with trading strategies, noting no compensation or business ties influencing his perspective. This cautious outlook underscores the need for investors to evaluate fundamentals carefully, amid changing market dynamics and varied sector performances.

Latest articles

Snap Drops 5%—Ad Recovery Eyed Next

Snap Drops 5%—Ad Recovery Eyed Next

8 June 2026
Snap closed Friday at $5.76, down 5.11% amid a broad tech selloff triggered by a strong jobs report and renewed rate-hike worries, but still ended the week up 0.9%. Investors now await U.S. inflation data and CEO Evan Spiegel’s June 16 AWE keynote on Specs, as Snap faces pressure from weak North American ad revenue, tough competition, and activist demands for cost cuts.
Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

Navitas’ Nvidia-Led Rally Stalls, Eyes on AI Trade Next Week

8 June 2026
Navitas plunged $5.61 to $25.08 Friday as a $1.3 trillion chip selloff erased Nvidia-driven gains, despite news it issued 3.28 million shares for merger earn-outs and showcased its GaNFast power board at Nvidia’s AI MGX event; investors now face risks from share dilution, sector volatility, and Navitas’s early-stage pivot to high-power AI markets amid ongoing operating losses.
NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

NIO Stock Drops Even as Deliveries Jump, Focus Turns to June Numbers

8 June 2026
NIO’s U.S.-listed shares plunged 5.8% Friday, erasing a delivery-led rally, as investors focus on whether June sales can hit the company’s Q2 target after May deliveries rose 62.3% to 37,705. NIO needs 42,939–47,939 June deliveries to meet guidance, with risks from China’s saturated car market and recent price pressure.
HPE Stock Faces AI Rally Test With Monday In Focus

HPE Stock Faces AI Rally Test With Monday In Focus

8 June 2026
Hewlett Packard Enterprise plunged 8.36% Friday to $49.20, capping a three-day slide and erasing gains after a post-earnings surge, even as it raised its fiscal 2026 revenue growth outlook to 29%-33% and boosted non-GAAP EPS guidance, with analysts warning that rapid gains may have priced in too much hope too quickly.
Go toTop